Monopar Therapeutics — Director's Dealing 2018

Jan 8, 2018

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Monopar Therapeutics (NONE)
CIK: 0001645469
Period of Report: 2018-01-08

Reporting Person: RIOUX PATRICE (N/A)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock options	$0.001		Common stock (7000)		Direct
Stock options	$6.00		Common stock (32004)		Direct

Footnotes

F1: Reflects the issuance of options to purchase up to 7,000 shares of common stock granted to Dr. Rioux on December 15, 2016 for his services as acting chief medical officer to Monopar Therapeutics. The options are fully vested as of June 15, 2017. The options each expire on December 14, 2026.

F2: Reflects the issuance of options to purchase up to 32,004 shares of common stock granted to Dr. Rioux on January 1, 2018 for his services as acting chief medical officer to Monopar Therapeutics. The options vest 12,000 shares on the grant date and and 1,667 options on the first of each month thereafter. The options each expire on December 31, 2027.